About
Andrew Sinclair, Ph.D., has served on Adicet Bio's board since March 2021. He is a partner at Abingworth LLP, a life-sciences investment group, where he has worked since November 2008 on investments in public and private biotech and pharmaceutical companies.
Before Abingworth he was a senior equity analyst and director at HSBC Global Markets covering the mid-cap pharmaceutical sector, and earlier held biotechnology analyst positions at Credit Suisse and SG Cowen. He received a B.Sc. in Microbiology from King's College London and a Ph.D. in Chemistry and Genetic Engineering, and qualified as a chartered accountant, formerly with KPMG.
Roles
Adicet Bio, Inc.
Director · Current role
2021–present
HSBC Global Markets
Senior equity analyst, director · Responsible for investment research in the mid-cap pharmaceutical sector.
—
Credit Suisse
Biotechnology analyst
—
SG Cowen
Biotechnology analyst
—
Sierra Oncology, Inc.
Board member · Company acquired by GSK plc.
2019-2022
Verona Pharma plc
Board member
2016-2022
External Roles
Abingworth LLP
Partner
—
Soleno Therapeutics, Inc.
Board member
—
Abingworth LLP
Partner and portfolio manager
—
Director Compensation
FY 2025Fees earned or paid in cash
$76,681
Stock awards
$4,630
Option awards
$15,715
Total
$97,027
Also at Adicet Bio, Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.